Premium
Effects of terguride, a partial D2 agonist, on MPTP‐lesioned parkinsonian cynomolgus monkeys
Author(s) -
Akai Tetsuo,
Yamaguchi Motonori,
Mizuta Eiji,
Kuno Sadako
Publication year - 1993
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410330515
Subject(s) - apomorphine , haloperidol , lisuride , dopamine agonist , mptp , parkinsonism , dopaminergic , pharmacology , stereotypy , agonist , medicine , dopamine , amphetamine , disease , receptor
Behavioral effects of terguride, a partial dopamine D2 agonist, on 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–lesioned parkinsonian cynomolgus monkeys were compared with those of the dopamine agonist apomorphine and the dopamine antagonist haloperidol. Terguride alone ameliorated the parkinsonism without inducing any sign of excitability, irritability, or aggressiveness (hyperactivity). Apomorphine alone also ameliorated the parkinsonism but induced marked hyperactivity. Haloperidol alone caused worsening of the parkinsonism, inducing transient eyelid closure. In combination with apomorphine, terguride suppressed the hyperactivity induced by apomorphine without reducing its antiparkinsonian effets. Pretreatment with haloperidol suppressed both the antiparkinsonian effects and the hyperactivity induced by apomorphine. Terguride thus exhibits both antiparkinsonian and antihyperactivity effects in a monkey model of Parkinson's disease, suggesting that terguride might be beneficial for treating motor dysfunction and dopaminergic psychosis in advanced Parkinson's disease.